{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:57:09Z","timestamp":1781305029280,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1003-5","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T14:07:17Z","timestamp":1534774037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin \u2013 case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Jonathan W.","family":"Goldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmah","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody A.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel M.","family":"Danovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik L.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung Cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"1003_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (ChckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1003_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomised phase II trial. J Clin Oncol. 2015;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. NEJM. 2015;372:311\u20139.","journal-title":"NEJM"},{"key":"1003_CR5","doi-asserted-by":"publisher","unstructured":"El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I\/II safety and antitumor activity of nivolumab in patietns with advanced hepatocellular carcinoma (HCC): CA209\u2013040. J Clin Oncol. 2015;33(18). \n                    https:\/\/doi.org\/10.1200\/jco.2015.33.18_suppl.lba101\n                    \n                  .","DOI":"10.1200\/jco.2015.33.18_suppl.lba101"},{"issue":"21","key":"1003_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi N, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. NEJM. 2015;372(21):2018\u201328.","journal-title":"NEJM"},{"issue":"10031","key":"1003_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma wo have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"10","key":"1003_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicenter, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1003_CR9","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. NEJM. 2016;375(19):1856\u201367.","journal-title":"NEJM"},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","volume":"105","author":"WB Coley","year":"1893","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;105:487\u2013511.","journal-title":"Am J Med Sci"},{"key":"1003_CR11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","volume":"366","author":"A Ribas","year":"2012","unstructured":"Ribas A. Tumor immunotherapy directed at PD-1. NEJM. 2012;366:2517\u20139.","journal-title":"NEJM"},{"issue":"9","key":"1003_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson EJ, Bagnasco SM, Moore J, et al. Tumor regression and allograft rejection after Administration of Anti\u2013PD-1. NEJM. 2016;374(9):896\u20138.","journal-title":"NEJM"},{"issue":"4","key":"1003_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/ajt.13711","volume":"16","author":"T Alhamad","year":"2016","unstructured":"Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant. 2016;16(4):1332\u20133.","journal-title":"Am J Transplant"},{"issue":"6","key":"1003_CR14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","volume":"27","author":"L Spain","year":"2016","unstructured":"Spain L, Higgins R, Gopalakrishnan K, et al. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27(6):1135\u20137. Pii:mdw130","journal-title":"Ann Oncol"},{"issue":"8","key":"1003_CR15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/ajt.13786","volume":"16","author":"CL Bollis","year":"2016","unstructured":"Bollis CL, Aljadir DN, Cantafio AW. Use of the PD-1 pathway inhibitor Nivolumab in a renal transplant patient with malignancy. Am J Transplant. 2016;16(8):2496\u20137. \n                    https:\/\/doi.org\/10.1111\/ajt.13786\n                    \n                  .","journal-title":"Am J Transplant"},{"issue":"2","key":"1003_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1056\/NEJMc1614298","volume":"376","author":"R Barnett","year":"2017","unstructured":"Barnett R, Barta VS, Jhaveri KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. NEJM. 2017;376(2):191\u20132.","journal-title":"NEJM"},{"issue":"9","key":"1003_CR17","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.transproceed.2016.07.019","volume":"48","author":"A Jose","year":"2016","unstructured":"Jose A, Yiannoullou P, Bhutani S, et al. Renal allograft failure after Ipilimumab therapy for metastatic melanoma: a case reports and review of the literature. Transplant Proc. 2016;48(9):3137\u201341.","journal-title":"Transplant Proc"},{"issue":"5","key":"1003_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","volume":"69","author":"EL Lum","year":"2017","unstructured":"Lum EL, Huang E, Bunnapradist S, et al. Acute kidney allograft rejection precipitated by Lenalidomide treatment for multiple myeloma. Am J Kidney Dis. 2017;69(5):701\u20134.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1003-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1003-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1003-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T23:10:39Z","timestamp":1566256239000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1003-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1003-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"1 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this manuscript have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"210"}}